Clozapine intoxication: theoretical aspects and forensic-medical examination

Close metadata

This literature review is focused on diagnostics of acute clozapine intoxication with the fatal outcome. According to the Russian authors, clozapine intoxication ranks first in the structure of criminal poisoning and accounted for 99.7% of all the cases that occurred in Moscow during the period from 2003 to 2006. Toximetric investigations of clinical manifestations of clozapine intoxication revealed that the threshold clozapine concentration in blood is 0.12±0.06 mg/l, the critical and lethal concentrations are 1.01±0.2 mg/l and 3.5±1.5 mg/l respectively. Autopsy on corpses of the victims of clozapine intoxication showed that most clozapine-induced pathological changes have a non-specific character (including largely circulatory disorders and dystrophic changes in parenchymatous organs). Clozapine poisoning is associated with the lengthening of QT-interval on ECG; at the values in excess of 500 ms, the risk of severe arrhythmia and sudden death significantly increases. Clozapine intake may lead to the development of potentially fatal myocarditis (the so-called clozapine-associated eosinophilic myocardium) in somatically healthy subjects. Foreign researchers report the possibility of a post-mortem increase of blood clozapine content compared with its antemortem level. They also showed that simultaneous use of substances stimulating activity of cytochrome P-450 enzymes (ethyl alcohol, finlepsin, fenitrin, nicotine) and clozapine accelerates metabolism and thereby reduces clozapine concentration in blood. It is concluded that comprehensive investigations of clozapine intoxication are needed taking into consideration pathomorphological changes induced by this agent, its potential interaction with other factors influencing human body, and the results of forensic chemical expertise of the fatal cases.

Keywords:

clozapine

leponex

azaleptin

concentration of clozapine

fatal poisoning

Authors:

Shigeev S.V.

FGBU "Rossiĭskiĭ tsentr sudebno-meditsinskoĭ ékspertizy" Minzdrava Rossii

Ivanova N.A.

Botkin Municipal Clinical Hospital, Moscow, Russia

Ivanov S.V.

State Research Institute for Complex Issues of Cardiovascular Diseases Municipal Budget Healthcare Institution, Kemerovo, Russia

List of references:

Ostapenko Yu.N., Litvinov N.N., Khonelidze Z.S., Gasimova Z.M. Informatsionnoe obespechenie toksikologicheskoi pomoshchi pri ostrykh otravleniyakh psikhotropnymi preparatami. V kn.: Diagnostika i lechenie ostrykh otravlenii lekarstvennymi preparatami psikhotropnogo deistviya. M 2002; 4-8.
Zimina L.N., Mikhailova G.V., Barinova M.V., Pavlenko E.Yu., Polozov M.A., Popov S.V., Rozumnyi P.A., Il'yashenko K.K., Ermokhina T.V. Morfologicheskie aspekty ostrykh otravlenii azaleptinom. Sud-med ekspert 2008; 3: 8-10.
Sokolova O.I. Opredelenie azaleptina pri sudebno-khimicheskom issledovanii: Avtoref. dis. … kand. farm. nauk. M 2007.
Slyundin D.G., Livanov A.S., Anuchin V.V., Bobrinskaya I.G., Gutova E.V. Kriminal'nye otravleniya klozapinom. Anesteziol i reanimatol 2007; 4: 61-64.
Ermokhina T.V. Ostrye otravleniya azaleptinom (diagnostika, klinika, lechenie): Avtoref. dis. … kand. med. nauk. M 2004.
Klozapin. Tipovaya kliniko-farmakologicheskaya stat'ya (TKFS). Avtoref. Obrashchenie lekarstvennykh sredstv: http://www.regmed.ru/InstrShow2.asp?InstrLinkNx=a51ba53ba74ba51b (data obrashcheniya 19.10.11).
Murzakhanov R.A. Klinicheskie aspekty otravleniya azaleptinom. V kn.: Aktual'nye voprosy vnutrennikh boleznei: Sbornik. Kazan': KGMU 2000; 249-252.
Fartushnyi A.F. Smertel'nye dozy i kontsentratsii nekotorykh lekarstvennykh veshchestv v biologicheskikh ob''ektakh. Sud-med ekspert 1999; 42: 5: 16-19.
Rauber-Lüthy C., Kupferschmidt H., Krähenbühl S., Ceschi A. Minimal dose for severe poisoning and influencing factors in acute human clozapine intoxication: a 13-year retrospective study. Clin Neuropharmacol 2010; 33: 5: 230-234.
Flanagan R.J., Spencer E.P., Morgan P.E., Barnes T.R., Dunk L. Suspected clozapine poisoning in the UK/Eire, 1992-2003. Forens Sci Int 2005; 155: 2-3: 91-99.
Prikaz Minzdrava RF №472 "O perechne lekarstvennykh sredstv spiskov A i B": ot 31.12.99: http://lawrussia.ru/bigtexts/law_195/index.htm (data obrashcheniya 16.05.13).
Prikaz Minzdravsotsrazvitiya Rossii №380 "O priznanii utrativshim silu prikaza ministerstva zdravookhraneniya Rossiiskoi Federatsii ot 24.05.10, №472 "O perechne lekarstvennykh sredstv spiskov A i B" ot 31.12.99: http://www.fmbaros.ru/2502/2559/item/807 (data obrashcheniya 24.10.11).
Il'yashenko K.K., Luzhnikov E.A., Belova M.V., Ermokhina T.V., Lisovik Zh.A., Kareva M.V., El'kov A.N., Zimina L.N., Barinova M.V. Osobennosti ostrykh otravlenii klozapinom. Toksikol vestn 2009; 2: 2-5.
Dailly E., Urien S., Chanut E., Claudel B., Guerra N., Femandez C., Jolliet P., Bourin M. Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuropsychopharmacol Biol Psychiat 2002; 26: 4: 699-703.
Hägg S., Spigset O., Söderström T.G. Association of venous thromboembolism and clozapine. Lancet 2000; 355: 9210: 1155-1156.
Renwick A.C., Renwick A.G., Flanagan R.J., Ferner R.E. Monitoring of clozapine and norclozapine plasma concentration-time curves in acute overdose. J Toxicol Clin Toxicol 2000; 38: 3: 325-328.
Lameh J., Burstein E.S., Taylor E., Weiner D.M., Vanover K.E., Bonhaus D.W. Pharmacology of N-desmethylclozapine. Pharmacol Ther 2007; 115: 2: 223-231.
Bonitenko Yu.Yu., Bonitenko E.Yu., Batotsyrenov B.V. Otravleniya azaleptinom. Klinika, diagnostika i lechenie. Medline.ru. 2006; 7: 1: www.medline.ru/public/art/tom7/art003pdf.phtml (data obrashcheniya 16.05.13).
Luk'yanchikov P.Yu. Ispol'zovanie gazozhidkostnoi khromatografii pri khimicheskom analize azaleptina. Probl ekspert v med 2004; 4: 3: 37-38.
Sokolova O.I., Malkova T.L., Nevolin N.I. Obnaruzhenie azaleptina pri sudebno-khimicheskom issledovanii trupnogo materiala. Sud-med ekspert 2007; 2: 35-38.
Barsegyan S.S., Nikolaeva N.O., Onishchenko M.M., Salomatin E.M., Sal'nikova E.A. Opredelenie klozapina pri sudebno-khimicheskom issledovanii trupnoi krovi, mochi i pecheni s primeneniem vysokoeffektivnoi zhidkostnoi khromatografii. Sud-med ekspert 2012; 4: 43-47.
Gorbacheva N.A., Orlova A.M., Lobacheva T.V., Goncharov V.M. Opredelenie azaleptina v eksgumirovannom trupnom materiale. Sud-med ekspert 2006; 2: 40-44.
Il'yashenko K.K., Luzhnikov E.A., Ermokhina T.V., Belova M.V., Davydov B.V., Matveev S.B., Fedorova N.V., Godkov M.A., Burykina I.A., Bitkova E.E., Burdyga F.A. Narusheniya laboratornykh pokazatelei pri otravleniyakh azaleptinom i smes'yu psikhotropnykh preparatov. Toksikol vestn 2007; 6: 29-33.
Dronova Yu.M. Sostoyanie glutationzavisimykh fermentov antioksidantnoi zashchity organizma v usloviyakh eksperimental'nogo modelirovaniya ostrogo otravleniya azaleptinom i amitriptilinom. V kn.: Novye tekhnologii v biologii i meditsine: materialy mezhregional'noi nauchno-prakticheskoi konferentsii molodykh uchenykh. Voronezh 2004; 38-40.
Bogomolova I.N., Bogomolov D.V. Tanatogenez pri otravlenii psikhofarmakologicheskimi sredstvami. Sud-med ekspert 2005; 2: 19-22.
Coodin S., Ballegeer T. Clozapine therapy and pulmonary embolism. Can J Psychiat 2000; 45: 4: 395.
Paciullo C.A. Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm 2008; 65: 19: 1825-1829.
Zimina L.N., Pavlenko E.Yu., Il'yashenko K.K. Morfologicheskie aspekty ostrykh otravlenii leponeksom i finlepsinom. Anesteziol i reanimatol 2005; 6: 35-37.
Abdelmawla N., Mitchell A.J. Sudden cardiac death and antipsychotics. Part 1. Risk factors and mechanisms. Adv Psychiatr Treat 2006; 12: 35-44.
Haas S.J., Hill R., Krum H., Liew D., Tonkin A., Demos L., Stephan K., McNeil J. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30: 1: 47-57.
Hägg S., Spigset O., Bate A., Soderstrom T.G. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21: 4: 382-388.
Kerswill R.M., Vicente M.R. Clozapine and Postmortem Redistribution. Am J Psychiat 2003; 160: 1: 184.
Pounder D.J., Jones G.R. Post-mortem drug redistribution - a toxicological nightmare. Forens Sci Int 1990; 45: 3: 253-263.
Flanagan R.J., Amin A., Seinen W. Effect of post-mortem changes on peripheral and central whole blood and tissue clozapine and norclozapine concentrations in the domestic pig (Sus scrofa). Forens Sci Int 2003; 132: 1: 9-17.
Ferner R.E. Post-mortem clinical pharmacology. Br J Clin Pharmacol 2008; 66: 4: 430-443.
Dagaev V.N., Luzhnikov E.A., Kazachkov V.I. Klinicheskaya toksikometriya ostrykh otravlenii. Ekaterinburg: Charoid 2001.
Molina D.K. Handbook of Forensic Toxicology for Medical Examiners (Practical Aspects of Criminal and Forensic Investigations). New York: CRC Press 2009.
Schulz M., Iwersen-Bergmann S., Andresen H., Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care 2012; 16: 136: http://ccforum.com/content/16/4/R136 (data obrashcheniya 16.05.13).
Schulte P. What is an adequate trial with clozapine?: therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet 2003; 42: 607-618.
Spina E., Avenoso A., Facciola G., Scordo M.G., Ancione M., Madia A.G. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology (Berl) 2000; 148: 83-89.
Ulrich S., Wolf R., Staedt J. Serum level of clozapine and relapse. Ther Drug Monit 2003; 25: 252-255.
Spisok odurmanivayushchikh veshchestv (po sostoyaniyu na 01.11.05) (utv. na zasedaniyakh Postoyannogo komiteta po kontrolyu narkotikov, protokol №2/98-2005). Nov lek prep 2005; 11: 52.
Postanovlenie Plenuma Verkhovnogo Suda Rossiiskoi Federatsii №29 "O sudebnoi praktike po delam o krazhe, grabezhe i razboe" ot 27.12.02. Ros gazeta №9 (3123) ot 18.01.03.

Close metadata